

Supplementary

Table S1 Classification based on postoperative Ctn

Group	Definition
Remission	Fall to normal and remain steady
Stable	Not fall to normal but keep steady
Progression	>150 pg/mL or doubling time was <12 months

Ctn, calcitonin.

Table S2 Logistic regression analysis of serum Ctn, tumor site, and multifocal MTC detection to predict TNM stage of MTC patients

Features	B	S.E.	Wald	P value	HR (95% CI)
Multifocal MTC					
No				Ref.	
Yes	1.056	0.990	1.137	0.286	2.874 (0.413, 20.013)
Tumor site					
Bilateral				Ref.	
Left	-0.772	1.508	0.262	0.609	0.462 (0.024, 8.881)
Right	-0.951	1.462	0.423	0.516	0.387 (0.022, 6.791)
Ctn (pg/mL)	0.004	0.001	12.753	<0.001	1.004 (1.002, 1.007)

Ctn, calcitonin; MTC, medullary thyroid carcinoma; TNM, tumor/node/metastasis; S.E., standard error; HR, hazard ratio; CI, confidence interval.

Table S3 Correlation between the preoperative serum Ctn groups and biochemical prognosis of MTC patients

Ctn (classification)	Remission	Stable	Progression	χ^2 value	P value
Ctn1 (pg/mL), n (%)				25.068	<0.001
≤195.5	39 (88.6)	1 (2.3)	4 (9.1)		
>195.5	11 (33.1)	6 (18.2)	16 (48.5)		
Ctn2 (pg/mL), n (%)				26.200	<0.001
<45.88	25(96.2)	0	1(3.8)		
45.88–167.00	8(80.0)	0	2(20.0)		
>167.00	13(35.1)	7(18.9)	17(46.0)		

Ctn, calcitonin; MTC, medullary thyroid carcinoma.